2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2489

In Clinical Practice a Substantial Group of Rheumatoid Arthritis (RA) Patients on Biologic Therapy (bDMARDs) Has Persistent Moderate Disease Activity Despite Treatment Switches That Correlates with Unfavourable Long-Term Outcome
Abstract Number: 910

In Diagnostic Prevalence and Treatment Patterns of Male and Female Ankylosing Spondylitis Patients in the United States, 2006-2016
Abstract Number: 2970

In Idiopathic Retroperitoneal Fibrosis, Persistent FDG PET Uptake Helps Identifying Patients at Risk for Relapse
Abstract Number: 394

In Patients with Suspected Idiopathic Inflammatory Myopathy, Does Pre-Biopsy Musculoskeletal MRI Result in Greater Yield of Diagnostic Biopsy Results? Summary of Data from a 10-Year Single Hospital Audit
Abstract Number: 321

In Rheumatoid Arthritis All Disease Activities Are Not Created Equal
Abstract Number: 2054

In Rheumatoid Arthritis, Changes in Autoantibody Levels Do Not Associate with Treatment Response, but Are a Reflection of Treatment Intensity
Abstract Number: 1351

In Situ Dendritic Cell Characterization in Idiopathic Inflammatory Myopathies
Abstract Number: 2307

In the 21st Century: Is Still Rheumatoid Arthritis a Risk Factor for Osteoporotic Fractures?
Abstract Number: 982

In the Presence of IL-18, IL-10 but Not IL-6 Induces IFN-γ Production and the Surface Expression of TRAIL on NK Cells
Abstract Number: 2048

In Vitro Proof-of-Concept of Pathobiology-Guided Therapy in Immune Mediated Inflammatory Arthritis
Abstract Number: 1115

In Vivo Assessment of Prevention of Lung Fibrosis Using the Pan-PPAR Agonist Lanifibranor in the Tβriiδk-Fib Mouse Model of Systemic Sclerosis
Abstract Number: 48

In Vivo Demonstration of Tmtnf Reverse Signaling: Significance in the Therapeutic Response to Anti-TNF Agents during Murine Arthritis
Abstract Number: 940

Inactivated Influenza Vaccine Prevents Respiratory Infections and Improves All-Cause and Cause-Specific Mortality in Immunosuppressed People with Autoimmune Rheumatic Diseases: Propensity Score Adjusted Cohort Study Using Data from Clinical Practice Research Datalink
Abstract Number: 2167

Incidence and Baseline Characteristics of Exacerbation in Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-Scale Cross-Sectional Cohort Study
Abstract Number: 2722

Incidence and Predictors of Severe Infections in ANCA Associated Vasculitis in a Population-Based Cohort – Preliminary Results

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].